An open-label, phase 2, single centre, randomised, crossover design bioequivalence study of AndroForte (R) 5 Compared With Testogel (R) 1% in Hypogonadal Men.

Trial Profile

An open-label, phase 2, single centre, randomised, crossover design bioequivalence study of AndroForte (R) 5 Compared With Testogel (R) 1% in Hypogonadal Men.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Testosterone (Primary) ; Testosterone
  • Indications Hypogonadism
  • Focus Pharmacokinetics
  • Sponsors Lawley Pharmaceuticals
  • Most Recent Events

    • 11 Sep 2012 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 06 Dec 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top